Transcatheter Aortic Valve Replacement in Low Risk Patients
The purpose of this study is to demonstrate that the safety and effectiveness of the Medtronic Transcatheter Aortic Valve Replacement (TAVR) system as measured by rates of all-cause mortality or disabling stroke at two years is non-inferior to Surgical Aortic Valve Replacement (SAVR) in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR.
This research study is led by Dr. Ashequl Islam.
Contact: Annette Scarnici, RN, CCRC, 413-794-9076
March 01, 2016
Baystate Medical Center, 759 Chestnut Street, Springfield, MA 01199
- At low risk for SAVR
- Severe aortic stenosis
Patients will be seen at pre and post-procedure, discharge, 30 days, and, 1 year.